She has a longstanding interest in developing better treatments for schizophrenia having served on the Board of Karuna Therapeutics prior to their successful acquisition by Bristol Myers Squibb ...

DelveInsight's 'IGALMI Market Size, Forecast, and Market Insight Report' highlights the details around IGALMI, a sublingual film formulation ...

April 22 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly watched late-stage trial that ...

Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 ...